Form 4: OS Therapies CFO Granted 100,000 Stock Options

OS Therapies Inc.'s Chief Financial Officer, Christopher P. Acevedo, was granted 100,000 stock options with a $1.34 exercise price.

Summary

• Christopher P. Acevedo, Chief Financial Officer of OS Therapies Inc. (OSTX), was granted 100,000 stock options.
• The options have an exercise price of $1.34 per share.
• The grant date for these options was January 22, 2026.
• These options will vest in full on January 22, 2027, provided Mr. Acevedo remains an employee of the issuer.
• The options have an expiration date of January 22, 2036.
• Following this transaction, Mr. Acevedo directly owns 109,375 shares of common stock and 100,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it signifies continued executive commitment and aligns management incentives with shareholder interests, which is generally well-received by the market.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages retention of key management personnel.

Future Outlook

The stock options are subject to a one-year vesting period, contingent on the Chief Financial Officer's continued employment with OS Therapies Inc., indicating an expectation of continued service.

Management Comments

• The reporting person was granted options to purchase 100,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement.
• These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.

Industry Context

StockSavvy.ai notes that equity grants to executive officers like the CFO are a standard practice across industries, particularly in growth-oriented companies, to attract, retain, and motivate key talent. This aligns management's financial incentives with the long-term performance of the company and shareholder value creation.

Comparison to Industry Standards

• The grant of 100,000 stock options to a CFO is a common compensation mechanism, comparable to practices at similar-sized biotech or emerging technology companies. For instance, a CFO at a pre-revenue or early-stage biotech firm might receive options ranging from 50,000 to 200,000 shares as part of their initial or annual equity compensation, depending on the company's valuation and stage.
• The one-year cliff vesting schedule is also a standard industry practice for initial grants, ensuring a minimum tenure for the executive to benefit from the equity.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of management's interests with shareholder value creation.
• Employees: May signal stability in executive leadership.

Next Steps

• The stock options will vest on January 22, 2027, contingent on the CFO's continued employment.
• The CFO may exercise the options at any time between the vesting date and the expiration date of January 22, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not provide sufficient new information to warrant a change in investment recommendation. It primarily indicates continued executive alignment and retention, which is a neutral to slightly positive signal, but not a catalyst for a strong buy or sell decision.

Keywords

OS Therapies Inc., OSTX, Christopher P. Acevedo, Chief Financial Officer, CFO, stock options, equity grant, insider transaction, Form 4, beneficial ownership